HPS-048 - A study on the impact of Dapagliflozin on HbA1c levels and proteinuria in patients with type 2 diabetes

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-048
• By: MEI-JUNG, Huang (Department Of Emergency Show Chwan Memorial Hospital, Changhua City Taiwan, China Taiwan)
• Co-author(s): Huang Mei-Jung (Department Of Emergency Show Chwan Memorial Hospital, Changhua City Taiwan, Changhua , China Taiwan)
  Dr Wang Chung-Hsuan (Department Of Emergency Show Chwan Memorial Hospital, Changhua City Taiwan, Changhua , China Taiwan)
  Pharmacist Huang Mei-Jung (Department Of Emergency Show Chwan Memorial Hospital, Changhua City Taiwan, Changhua , China Taiwan)
  
• Abstract:

  Introduction
  Dapagliflozin is a selective sodium/glucose cotransporter 2 (SGLT2) inhibitor that reduces the reabsorption of filtered glucose in the proximal renal tubules, promoting urinary excretion of glucose and thereby reducing blood glucose levels. Clinical trials have shown that dapagliflozin can slow the progression of kidney disease.
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login